Leo Cui

General Partner | Deep-tech and AI investments

2022

FoundersX Ventures is a cross stage venture capital firm based in Silicon Valley. Our investments have strong focus on game-changing technologies in high growth industries, including quantum computing, enterprise SaaS, Fintech, biotech, telehealth, and low-carbon solutions. We are strategic investors, adding values in bringing in global capital and enterprise partners, and access to top engineering talent in Stanford, Berkeley, Harvard and MIT. Our investment team is highly engaging and operation driven. We enjoy empowering daring tech founders to change the world!

Venture Capital Fellow | Deep-tech venture

2020 - 2022

Advisory Council

2024

Help chart Harvard Business Review’s future direction!

Investor

2023

We use AI to help you write patents. We do this by providing a simple in-browser document editor that any patent attorney or inventor can start using straight away. Our product can help with all stages of the patent life cycle, from drafting and filing to prosecution and opposition. If you are an an inventor, a patent attorney, or even just an enthusiast interested in the intersection of AI and intellectual property, we would love to hear from you: https://www.solveintelligence.com/contact-us

Investor

2022

Our mission is to make AI radically cheaper. We are the world leaders in algorithm/hardware co-design for artificial intelligence. Our roadmap begins with products 100x better than GPUs and will ultimately deliver products that are many orders of magnitude more cost effective than what is available today. We will ultimately be able to put models the size of ChatGPT into chips the size of a thumbnail.

Investor

2023

TechBio company decoding the immune system in high resolution to inform therapy and develop diagnostics through the convergence of immune cell sequencing and artificial intelligence. We bring together bright minds from multiple disciplines. We are driven to shorten the timeline from research to real-world human impact. Our motivation is to put science in service of humanity.

Investor

2023

We are a lifesciences products company specializing in building tools and generating insights at the interface of biology, chemistry and engineering. We work extensively in cellular analysis and in understanding how genetic code becomes functional output.

Investor

2022

Building a sustainable future in space. Building spacecraft for space situational awareness and in space logistics.

Investor

2024

We sequence proteins. Glyphic Biotechnologies is a biotechnology startup revolutionizing the field of proteomics. While DNA can reveal biological insights, proteins actually tell us what our bodies will do. We are developing a first-of-its-kind, next-generation protein sequencing platform to enable researchers to gain novel insights into biology and disease.

Investor

2024

Arintra’s medical coding software offers two powerful modes for medical coding: autonomous coding mode and assisted coding mode. In autonomous coding mode, direct-to-billing claims are generated autonomously with high accuracy, streamlining the billing process for healthcare provider organizations. Whereas, assisted coding mode allows medical coders to meticulously review and optimize charges before submission, leading to increased efficiency and precision in the coding process. With Arintra, healthcare provider organizations can rely on precise direct-to-billing claims that include essential codes like E/M levels, CPT, ICD-10, HCC, HCPCS with appropriate modifiers and units. Arintra’s coding solution provides extensive coverage and flexibility, catering to various coding domains such as professional coding, professional-fee coding, facility coding, and inpatient coding.

Investor

2022

Breakthrough medical device company for AD, Dementia, PD and other neural disorders. MIT Spin-off. Raised $70M at B round with remarkable phase II human trial data. Currently in Phase 3 trial.